Stocktoria
EXPONENT INC EXPO
EXPONENT INC (EXPO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 2.09% (safety: moderate). FY2026 revenue was $582.0M at a 18.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-15 | JP Morgan | Overweight (main) |
| 2026-05-01 | UBS | Neutral (main) |
| 2026-03-26 | JP Morgan | Overweight (main) |
| 2026-01-26 | JP Morgan | Overweight (init) |
| 2025-12-15 | UBS | Neutral (main) |
| 2025-11-17 | William Blair | Outperform (up) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.321 |
| Retained earnings / assets | 0.86 |
| EBIT / assets | 0.154 |
| Equity / liabilities | 1.008 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EXPO | EXPONENT INC | 5/9 | 7 | 27.8 | +4.2% |
| BWMN | Bowman Consulting Group Ltd. | 6/9 | 1.01 | 40.8 | +14.9% |
| RMR | RMR GROUP INC. | 3/9 | 4.47 | 38.1 | -22% |
| ONT | Onterris, Inc. | 4/9 | 0.55 | — | +19.3% |
| HCKT | HACKETT GROUP, INC. | 5/9 | 3.64 | 22 | -2.6% |
| TSSI | TSS, Inc. | 6/9 | 1.81 | 21 | +65.9% |
| III | Information Services Group Inc. | 5/9 | 1.7 | 21.5 | -1.2% |
About EXPONENT INC
Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.
FAQ
Is EXPO financially healthy?
EXPONENT INC's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does EXPO pay a dividend, and is it safe?
Yes. EXPONENT INC pays a dividend yielding about 2.09% with a 58.1% payout ratio, rated “moderate” for safety.
How profitable is EXPO?
In FY2026, EXPONENT INC had a net margin of 18.2% and a return on equity of 27.2%.
Is EXPO overvalued or undervalued?
EXPONENT INC trades at about 32.7× trailing earnings — below its 10-year norm (10-year range 33.4×–53.3×, median 47.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for EXPO?
The average Wall-Street price target for EXPONENT INC is $81.67, about 20.7% above the recent price, from 3 analysts.
Is EXPO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on EXPONENT INC: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 27.8×, a dividend yield of 2.09%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-01-02. Facts plus Stocktoria's own computed scores — not investment advice.